Page 338 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C1.14. Treatment characteristics—changes in treatment patterns over time (continued)
Author Database Treatment 1980- 1985-89 1990-94 1995- 2000-04 2005- Statistical Notes
Year 84 99 10 analysis
PMID
CaPSURE AS/WW 4.4% 5.7% 3.3% 5.9% NR
(CAPRA 3-5) RP 54.9% 47.2% 48.6% 48.7%
RT 24.1% 28.6% 26.9% 23.5%
ADT 9.4% 14.7% 17.2% 14.9%
(1990-94) (1995- (2002-03) (2004-
99) 07)
CaPSURE AS/WW 1.7% 2.7% 1.1% 1.9% NR
(CAPRA 6- RP 27.5% 22.1% 23.3% 22.9%
10) RT 29.7% 28.6% 25.2% 21%
ADT 36.7% 41.9% 43% 45.5%
(1990-94) (1995- (2002-03) (2004-
99) 07)
71
Greene CaPSURE RP 52% 58% P=0.011
2005 Cryosurgery 2% 3% (chi-square
16194711 BT 27% 21% comparing 2
EBRT 13% 10% periods)
Orchiectomy 0% <1%
LHRH agonist 3% 4%
LHRH 1% <1%
antagonist 1% 1%
Antiandrogen <1% <1%
5α-RI 1% 2%
WW (1997- (2000-03)
99)
72
Mettlin NCDB TURP only 32.1% 20.4% NR
1994 RP 11.1% 23.7%
8062197 RT 26.8% 28.0%
RP+RT 2.1% 2.4%
ADT 17.0% 16.0%
RT+ADT 5.0% 3.4%
RP+ADT 0.7% 1.3%
RP+RT+ADT 0.2% 0.2%
Other 5.0% 4.6%
(1985) (1990)
73
Mettlin NCDB RP 12.4% 29.4% NR
1996 RT 27.3% 30.6%
8640686 No Tx 38.0% 20.8%
(1987) (1992)

C-87